 |
|
Systemic therapy in advanced hepatocellular carcinoma
Joseph C. Ahn, Nguyen H. Tran, Ju Dong Yang
Clin Mol Hepatol. 2023;29(2):516-519. Published online 2023 Feb 20 DOI: https://doi.org/10.3350/cmh.2023.0051
|
|
Citations to this article as recorded by
 T cell-related ubiquitination genes as prognostic indicators in hepatocellular carcinoma
Chaobo Chen, Zheng Chen, Zheyu Zhou, Hui Ye, Shaohui Xiong, Weidong Hu, Zipeng Xu, Chen Ge, Chunlong Zhao, Decai Yu, Jiapei Shen
Frontiers in Immunology.2024;[Epub] CrossRef CCL5/CCR5/CYP1A1 pathway prompts liver cancer cells to survive in the combination of targeted and immunological therapies
Yafei Wang, Biao Gao, Tianyu Jiao, Wenwen Zhang, Huizhong Shi, Hao Jiang, Xuerui Li, Junfeng Li, Xinlan Ge, Ke Pan, Chonghui Li, Guankun Mao, Shichun Lu
Cancer Science.2024;[Epub] CrossRef Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clinical and Molecular Hepatology.2023; 29(2): 252. CrossRef The prime time for management of hepatocellular carcinoma in Hong Kong
Landon L. Chan, Stephen L. Chan
Clinical and Molecular Hepatology.2023; 29(2): 345. CrossRef What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
Min Kyung Park, Yoon Jun Kim
Clinical and Molecular Hepatology.2023; 29(2): 332. CrossRef
|